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Abstract
Throughout the 1990 s, there was an epidemic of multidrug resistant Salmonella Typhimurium DT104 in both animals and
humans in Scotland. The use of antimicrobials in agriculture is often cited as a major source of antimicrobial resistance in
pathogenic bacteria of humans, suggesting that DT104 in animals and humans should demonstrate similar prevalences of
resistance determinants. Until very recently, only the application of molecular methods would allow such a comparison and
our understanding has been hindered by the fact that surveillance data are primarily phenotypic in nature. Here, using large
scale surveillance datasets and a novel Bayesian approach, we infer and compare the prevalence of Salmonella Genomic
Island 1 (SGI1), SGI1 variants, and resistance determinants independent of SGI1 in animal and human DT104 isolates from
such phenotypic data. We demonstrate differences in the prevalences of SGI1, SGI1-B, SGI1-C, absence of SGI1, and
tetracycline resistance determinants independent of SGI1 between these human and animal populations, a finding that
challenges established tenets that DT104 in domestic animals and humans are from the same well-mixed microbial
population.
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Introduction
Multidrug resistant Salmonella Typhimurium DT104 was first
identified in the 1980 s [1]; following its identification it became
one of the most commonly isolated serovars of Salmonella from
cases of human and animal clinical infection over the following
two decades in Europe and North America [2]. Its zoonotic
potential and epidemiology are well established; cattle density and
contact with cattle or other animals are identified risk factors for
human infection with DT104 in the UK [3–5] and elsewhere [6–
8]. The epidemic of DT104 that occurred in Scotland from the
late 1980 s to the mid 2000 s provides an opportunity to chart the
rise and fall of a zoonotic pathogen in both humans and animals.
Furthermore, as a clonal bacterial infection that is frequently
multiresistant to antimicrobials, and one that is reportable in both
medical and veterinary domains, the identification and distribu-
tion of resistance phenotypes between species is also possible. This
is important because the agricultural and veterinary use of
antimicrobials is often cited as a major driver of the emergence
and spread of multidrug resistant bacteria in humans [9–13]. A
key issue in considering the relative contribution to antimicrobial
resistance (AMR) in both animals and humans is the similarity, or
otherwise, of the distribution of resistance phenotypes, and
resistance determinants in the two populations. This question
can only be addressed by the use of sympatric and contempora-
neous surveillance data.
There are several resistance phenotypes of DT104 described in
the literature. The most common resistance pattern involves
resistance to ampicillin (A), chloramphenicol (C), spectinomycin
(Sp), streptomycin (St), sulphonamides (Sx) and tetracycline (T),
which are chromosomally encoded, the genes residing in a region
termed Salmonella genomic island 1 (SGI1) [14]. Although
phenotypic resistance to A, C, Sp, St, Sx, and T strongly suggest
that SGI1 is present in a DT104 isolate [15,16], it is possible that
these resistances arose independently and the genes are located
outwith SGI1. As a consequence, hitherto it has not been possible
to determine the genotype of an isolate given its phenotype, as
several different genes with distinct resistance mechanisms may be
responsible for the same phenotype. This is unfortunate as most
AMR data collected are phenotypic, particularly in clinical
surveillance systems. Whilst high throughput genotyping does
offer a solution to this problem, cost and availability currently limit
the opportunities to exploit fully this technology. Here, using a
method capable of inferring genotypes from phenotypic data [17],
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we assess the prevalence of SGI1 and its variants, as well as the
prevalence of SGI1-independent resistance determinants, in
sympatric and contemporaneous animal and human populations,
thereby contrasting the epidemics of the organism in two species.
In doing so, we examine established tenets that DT104 in domestic
animals and humans are from the same well-mixed microbial
population.
Materials and Methods
Data collection
The data used in this study were part of an ongoing passive
surveillance effort for Salmonella. A total of 2,439 animal and
2,761 human Salmonella Typhimurium DT104 isolates were
submitted to the Scottish Salmonella, Shigella and Clostridium
difficile Reference Laboratory (SSSCDRL) from 1990 to 2004,
covering the epidemic period of DT104. Identified human
Salmonella isolates from diagnostic medical laboratories were sent
to the SSSCDRL for confirmation and further testing, and animal
isolates were submitted to the SSSCDRL from veterinary
laboratories. The SSSCDRL is fully accredited with Clinical
Pathology Accreditation (UK) Ltd. Only human isolates from
domestic cases with no recent history of foreign travel were
included in this study. Serotyping of the isolates was accomplished
according to internationally standardised methods based on the
Kauffman-White scheme [18], and phage typing was carried out
according to standardised protocols [19,20] at the SSSCDRL.
Susceptibility testing
Antimicrobial susceptibility was assessed at the SSSCDRL for
both animal and human isolates using a modified breakpoint
method, involving solid agar plates containing a pre-determined
concentration of antimicrobial. The breakpoint for ampicillin was
50 mg/mL; chloramphenicol, 20 mg/mL; spectinomycin, 100 mg/
mL; streptomycin, 20 mg/mL; sulphamethoxazole, 100 mg/mL;
tetracycline, 10 mg/mL. Suspensions of Salmonella were inocu-
lated onto the surface of the plates; bacterial growth, following
incubation, indicated resistance to that antimicrobial at that
concentration [21]. Categories of resistance to each antimicrobial
were non-resistant or resistant, with a resistance profile defined as
a unique combination of resistances.
Assessing linkages between antimicrobial resistances
A full description of the statistical techniques and program code
is given in Denwood et al. [17]. Briefly, Bayesian Markov chain
Monte Carlo (MCMC) methods were used to extract information
about the hidden variable state (resistance genotype), from the
observed variable state (resistance phenotype), using a hierarchical
mixture model. The goal was to estimate the prevalence of SGI1
and each of the SGI1 variants of DT104 previously identified in
the literature (Table 1) [22–32], and the prevalence of resistance
determinants outside of SGI1 in both the animal and human
datasets. Variants found in other Salmonella serovars, or other
bacteria, were excluded, and the presence of resistance genes to
antimicrobials other than the six antimicrobials in the full SGI1 (A,
C, Sp, St, Sx, T) were not considered.
For each antimicrobial, a [ {1,2,3,4,5,6} (where 1=Ampicillin,
2 =Chloramphenicol, 3 = Spectinomycin, 4 = Streptomycin, 5 =
Sulphonamides and 6=Tetracycline), tested for each isolate, i, the
probability of observing a resistance to antimicrobial a in isolate i,
P(Rai), is given by:
P Raið Þ~1{½1{P Gað Þ½1{P Saið Þ
where Sa refers to observation of resistance to a when it is encoded
by SGI1, and Ga refers to the observation of resistance to a when it
is encoded elsewhere on the genome. The latter event represents
the combined probability of one or more such genes existing and
the probability of phenotypic expression of these genes given that
they exist.
The probability of observing a resistance encoded by SGI1,
P(Sai), for each antimicrobial is now conditional on the type of
SGI1 variant, V [ {1,2,3,4,5,6,7} (see Table 1), as well as
depending on the probability of expression for that antimicrobial,
Ea. For each isolate, i,
P(S1 i)~
P(E1), if V[f2,3,5,6g
0, if V[f1,4,7g

P(S2 i)~
P(E2), if V[f2,6,7g
0, if V[f1,3,4,5g

P(S3 i)~
P(E3), if V[f2,4,5,7g
0, if V[f1,3,6g

P(S4 i)~
P(E4), if V[f2,4,5,7g
0, if V[f1,3,6g

P(S5 i)~
P(E5), if V[f2,3,4,5,6g
0, if V[f1,7g

P(S6 i)~
P(E6), if V[f2,5,6,7g
0, if V[f1,3,4g

The probabilities P(Ga) and P(Ea) are estimated using minimally
informative Beta priors and the multinomial probability vector
P(V= v) for v=1,…,7 estimated using a minimally informative
Dirichlet prior [17]. Although resistance to Sp and St is mediated
by the same gene (aadA2) in SGI1, Sp and St resistances are
included in the model individually. This is partly due to the
different phenotypic breakpoints used for the two antimicrobials;
by including both Sp and St separately, we allow for the possibility
of a profile that has phenotypic resistance to one but not the other.
These resistances could be either due to a SGI1 variant (where the
gene is present, but its phenotypic expression is not sufficiently
high enough for one to be detected), or to be due to genes outside
of SGI1. The pseudo-parameters P(S3i) and P(S4i) are presented
separately above, but the two are inseparably linked due to being
dependent on the same gene, i.e., if P(S3i) = 0, then P(S4i) = 0.
However, if the two are not equal to zero then each maps directly
onto the corresponding probability of phenotypic expression P(E3)
and P(E4), which represents the possibility of a difference in
phenotypically detecting the presence of the gene, given that the
breakpoints are different for the two antimicrobials.
The model allowed each observed phenotypic profile to occur
as a result of: i) one of seven possible variants of SGI1 that have
been previously reported in the literature (the full SGI1, five
variants, and no SGI1); ii) as a result of individual resistance
elements, not related to SGI1, to one or more of the six
antimicrobials of interest; iii) as a combination of the two. Each
SGI1 Variants in Animal and Human DT104 Isolates
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resistance determinant outside of SGI1 was assumed to arise
independently of the presence or absence of other phenotypic
resistances. Minimally informative priors were used for the
prevalences of the various SGI1 variants and the prevalences of
resistance determinants outside of SGI1, thus ensuring the
prevalences were determined predominantly by the data. The
probabilities of phenotypic expression for resistance determi-
nants within SGI1, given that the determinant was present, were
assumed to be independent, and unrelated to the probabilities of
phenotypic expression for resistance arising from a gene not
linked to SGI1. The model was implemented by MCMC
simulation, using seven chains with over-dispersed initial values.
Convergence was determined by a Gelman Rubin statistic of
less than 1.05 for each parameter, in addition to visual
inspection of the trace plots for each parameter. Model
goodness-of-fit was assessed using posterior predictive p-values
based on the number of unique profiles, as described and
discussed extensively by Denwood et al. [17]. Briefly, for the
animal and human models separately, posterior predictive p-
values were calculated using the output of the MCMC model as
follows: The combination of parameter values from a single
iteration were used to obtain 1,000 bootstrapped datasets equal
in size to the observed sample size (2,761 for the human data,
2,439 for the animal data). The distribution of the number of
unique resistance profiles per bootstrapped dataset was then
compared to the observed number of unique profiles. Monte
Carlo integration was used to obtain a p-value, reflecting the
probability that a dataset as, or more extreme than, the
observed dataset would be obtained using the parameter values
at that iteration. This process was repeated for the combination
of parameter values at a total of 1,000 iterations, and the
resultant 1,000 p-values along with an ‘overall’ p-value were
generated for each model.
Results
The median and 95% credible intervals (CI) for each parameter
estimated for the human and animal data are shown in Table 2.
The predicted prevalences of the resistance determinants inde-
pendent of SGI1 for both animal and human isolates are
compared in Figure 1, and the predicted prevalences of SGI1
variants and the absence of SGI1 for both animal and human
isolates are compared in Figure 2. The results of the analysis
revealed differences in the estimated prevalences for certain
resistance determinants between bacteria derived from animals
and humans, namely, for three of the six SGI1 variants, and also
the prevalence of isolates without SGI1. The median prevalence of
the full SGI1 in human isolates was 0.90, whereas in the animal
isolates, the median was higher at 0.97, with the 95% credible
intervals non-overlapping. Conversely, in human isolates, the
estimated prevalences of SGI1-B and SGI1-C were higher than in
animal isolates, where for both variants the prevalences were
estimated to be very low (95% CIs non-overlapping). SGI1-E,
SGI1-M, and SGI1-T were both estimated to be present at
extremely low prevalence or absent from both the human and
animal isolate populations studied. In addition, the prevalence of
tetracycline resistance associated with a gene outside the SGI1 was
estimated to be higher in animal than in human isolates (95% CIs
non-overlapping).
Table 1. SGI1 and SGI1 variants found in Salmonella Typhimurium DT104 with their resistance phenotypes to the six
antimicrobials in the full SGI1 [ampicillin (A), chloramphenicol (C), spectinomycin (Sp), streptomycin (St), sulphonamides (Sx) and
tetracycline (T)] and resistance genes as reported in the literature.
Variant name Variant number Phenotype Resistance genes Reference
Absence of SGI1 1 – – –
SGI1 2 ACSpStSxT blaPSE-1, sulI, aadA2, floR, tetR, tetG [23]
SGI1-B 3 ASx blaPSE-1, sulI [22,25–27,29,30]
SGI1-C 4 SpStSx aadA2, sulI [22,24,26,27,29,30,32]
SGI1-E 5 ASpStSxT blaPSE-1, sulI, aadA2, floR (interrupted), tetG [22]
SGI1-M 6 ACSxT blaPSE-1, floR, tetR, tetG, sulI, aadB* [31]
SGI1-T 7 CSpStT floR, tetR, tetG, aadA2 [28]
*conferring resistance to kanamycin, gentamicin, and tobramycin; this information not used.
doi:10.1371/journal.pone.0027220.t001
Table 2. The median and 95% credible interval (CI) estimates
for each parameter estimated from the analysis of the 2,761
human and 2,439 animal Salmonella Typhimurium DT104
resistance profiles, for the six antimicrobials ampicillin (A),
chloramphenicol (C), spectinomycin (Sp), streptomycin (St),
sulphonamides (Sx), and tetracycline (T).
Human Animal
Parameter Median (95% CI) Median (95% CI)
Independent A 0.02 (0.01–0.05) 0.04 (0.00–0.14)
Independent C 0.01 (0.00–0.02) 0.01 (0.00–0.07)
Independent Sp 0.01 (0.00–0.05) 0.05 (0.00–0.15)
Independent St 0.05 (0.02–0.09) 0.19 (0.09–0.33)
Independent Sx 0.05 (0.02–0.11) 0.18 (0.06–0.35)
Independent T 0.04 (0.02–0.07)* 0.22 (0.13–0.33)*
No SGI1 variant 0.04 (0.03–0.05)* 0.01 (0.01–0.02)*
Full SGI1 variant 0.90 (0.89–0.91)* 0.97 (0.97–0.98)*
SGI1-B variant 0.02 (0.02–0.03)* 0.01 (0.00–0.01)*
SGI1-C variant 0.04 (0.03–0.05)* 0.01 (0.00–0.01)*
SGI1-E variant 0.00 (0.00–0.00) 0.00 (0.00–0.00)
SGI1-M variant 0.00 (0.00–0.00) 0.00 (0.00–0.00)
SGI1-T variant 0.00 (0.00–0.00) 0.00 (0.00–0.00)
*95% credible intervals non-overlapping between animal and human isolates.
‘Independent’ probabilities refer to the combined probability of a resistance
determinant occurring outside of SGI1 and that being expressed in the
phenotype. ‘Variant’ probabilities refer to the prevalence of each SGI1 variant.
doi:10.1371/journal.pone.0027220.t002
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The posterior predictive p-values for both the animal and
human models were not statistically significant (p = 0.16 and
p= 0.53, respectively), indicating that the models adequately
describe the number of unique resistance phenotypes observed.
Discussion
We demonstrate that during the epidemic of DT104 in
Scotland, there were differences between isolates from animals
and humans in the estimated prevalences of the three most
common variants of SGI1 and of the absence of SGI1, as well as
differences in the prevalence of tetracycline resistance determi-
nants occurring independently of SGI1. The prevalence of the
most common variant, the full SGI1, was estimated to be higher
in animals than in humans, and was the most commonly
predicted genotype in both populations. Although some may
consider the estimated prevalences of SGI1 to be qualitatively
similar, the fact that highly significant differences have been
demonstrated between the populations is a strong indication
that the two populations are not as well-mixed as has been
suggested previously [10,13]. The median prevalence of isolates
not containing any SGI1 variant was 4% in humans, whereas in
the animal isolates it was lower at 1%, with the 95% credible
intervals non-overlapping. There were also differences in the
prevalences of SGI1-B and SGI1-C between animal and human
isolates, with the prevalences of both being higher in human
isolates and there were differences in the prevalence of non-
SGI1-related resistance determinants between the two popula-
tions. For example, the prevalence of tetracycline resistance due
to a gene independent of SGI1 was higher in animal isolates
than in human isolates. Established tenets, that the domestic
animal population is a major source of the resistance in DT104
found in humans and that the microbial communities are well
mixed, are widespread in the literature [10,13,33–35]. Were this
the case we might expect similar prevalences of the various
SGI1 variants and SGI1-independent resistance determinants in
both animal and human isolates, but this was clearly not what
we observed. Without making any claim regarding transmission,
in either direction, of resistance determinants between the two
populations, and acknowledging the existence of additional
sources of resistance such as imported food, our observation
does point to independent or differing processes occurring
within each population during the epidemics with respect to
evolution and dissemination.
Figure 1. Predicted prevalences of resistance to individual antimicrobials. Posterior densities of the predicted prevalences of
phenotypically expressed resistance determinants independent of SGI1 in Scottish S. Typhimurium DT104 data, 1990–2004, from animals (dashed
line) and humans (solid line), to each of the six examined antimicrobials.
doi:10.1371/journal.pone.0027220.g001
SGI1 Variants in Animal and Human DT104 Isolates
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The data we have used are the most suitable of any available
for such a comparison. The isolates were collected from animals
and humans from the same geographical area over the same
time period, which covered the majority of the DT104
epidemic. They were also subject to the same microbiological
and susceptibility testing techniques in the same laboratory; use
of a single laboratory should minimise any bias relating to
observed AMR differences between animal and human isolates,
conditional on the method used. We infer genotype from the
phenotype utilising the prior knowledge of the genetics of
resistance in DT104, which has been very well characterised
[14,23,34,36]. Our approach represents a methodological
advance in the analysis of phenotypic AMR data, allowing the
prevalence of genetic elements to be inferred at the resolution of
the population, rather than predicting the genotype of
individual isolates. The ability to infer genotypic information
from phenotypic data at this level will provide a greater insight
into differences in the evolution and spread of resistance within
and between populations.
In the context of DT104, it has been particularly interesting to
have conducted this analysis on data spanning the entirety of the
epidemic curve. However, a number of caveats remain. The
nature of isolate collection and reporting present potential biases;
because the isolates were passively collected and are likely to be
predominantly diagnostic isolates from clinically ill individuals, it is
possible that these results may not represent the characteristics of
DT104 which are present in the general (healthy) population,
although a recent study of Salmonella Typhimurium suggests that
this may not be the case [37]. The differing prevalences of the
various resistance determinants in animal and human DT104
isolates may be due to different antimicrobial usage patterns; it is
possible that animals, having a higher prevalence of the full SGI1,
are more likely than humans to have received antimicrobial
treatment prior to a sample being submitted. However, there are
no antimicrobial use data available to test a hypothesis regarding
antimicrobial use and resistance. It is also possible that the
disparity in results between the two populations could be due to a
systematic difference in reporting of isolates in animals and
humans, or to epidemiological differences in characteristics such as
duration of infection or shedding patterns that may be affected by
SGI1.
Nevertheless, these caveats are intrinsic to surveillance data of a
phenotypic nature and, despite this, it is data of this kind that are
used to support the alternative views and form the basis for policy
[38,39]. Molecular genotypic data would provide additional
information on the comparison of the different genotypes in these
populations and could be considered to be the gold standard.
However, given the very low prevalence of the rarer phenotypes
and inferred genotypes we describe here, the number of isolates
that would be required to validate our approach would be
unfeasibly large. In more general terms, our approach is
advantageous because large-scale genotyping is, and has been,
uncommon in surveillance programmes due to financial and
logistical constraints, and is unlikely to be applied retrospectively.
In addition, the methods we describe would be particularly
relevant for the analysis of historic data where isolates are no
longer available or viable.
In conclusion, we demonstrate differences between resistant
Salmonella Typhimurium DT104 in human and animal populations
during the epidemics that occurred in Scotland. These findings
suggest that although these populations share a common
ecological niche, the epidemiologies of the organism, the resistance
determinants, or both, are distinguishable. Our approach has
allowed previously unavailable data on genotype to be extracted
from phenotypic data; based on this combination of phenotypic
and genotypic data, our findings reinforce the need to understand
the biology underlying the epidemics and the relative importance
of each microbiological population in the different host species
before implementing policy on antimicrobial usage.
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Figure 2. Predicted prevalences of SGI1 variants. Posterior densities of the predicted prevalences of SGI1, SGI1 variants, and absence of SGI1 in
Scottish S. Typhimurium DT104 data, 1990–2004, from animals (dashed line) and humans (solid line).
doi:10.1371/journal.pone.0027220.g002
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